Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848107 | 1.00 | CYP1A2 (0.45) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL9542869 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL7380297 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL6847724 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL3194307 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL12646680 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL8642743 | 0.90 | ACE (0.54) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL6842694 | 0.89 | KMT2A (0.43) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL13357763 | 0.89 | ACE (0.46) | CYP1A2POLBCYP3A4CYP2C19ACE | |
| SCHEMBL3182686 | 0.89 | ACE (0.43) | CYP1A2POLBCYP3A4CYP2C19ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |